Please use this identifier to cite or link to this item:
Title: Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum
Authors: MONTEIRO, Lis MarieLOBENBERG, RaimarBARBOSA, Eduardo JoseARAUJO, Gabriel Lima Barros deSATO, Paula KeikoKANASHIRO, EditeELIODORO, Raissa H. de AraujoROCHA, MussyaFREITAS, Vera Lucia Teixeira deFOTAKI, NikolettaBOU-CHACRA, Nadia Araci
Citation: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, v.169, article ID 106097, 11p, 2022
Abstract: Leishmaniasis, a neglected tropical disease, is prevalent in 98 countries with the occurrence of 1.3 million new cases annually. The conventional therapy for visceral leishmaniasis requires hospitalization due to the severe adverse effects of the drugs, which are administered parenterally. Buparvaquone (BPQ) showed in vitro activity against leishmania parasites; nevertheless, it has failed in vivo tests due to its low aqueous solubility. Though, lipid nanoparticles can overcome this holdback. In this study we tested the hypothesis whether BPQ-NLC shows in vivo activity against L. infantum. Two optimized formulations were prepared (V1: 173.9 +/- 1.6 nm, 0.5 mg of BPQ/mL; V2: 232.4 +/- 1.6 nm, 1.3 mg of BPQ/mL), both showed increased solubility up to 73.00-fold, and dissolution up to 83.29%, while for the free drug it was only 2.89%. Cytotoxicity test showed their biocompatibility (CC50 >554.4 mu M). Besides, the V1 dose of 0.3 mg/kg/day for 10 days reduced the parasite burden in 83.4% +/- 18.2% (p <0.05) in the liver. BPQ-NLC showed similar leishmanicidal activity compared to miltefosine. Therefore, BPQ-NLC is a promising addition to the limited therapeutic arsenal suitable for leishmaniasis oral administration treatment.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MIP
Departamento de Moléstias Infecciosas e Parasitárias - FM/MIP

Artigos e Materiais de Revistas Científicas - IMT
Instituto de Medicina Tropical - IMT

Artigos e Materiais de Revistas Científicas - LIM/46
LIM/46 - Laboratório de Parasitologia Médica

Artigos e Materiais de Revistas Científicas - LIM/48
LIM/48 - Laboratório de Imunologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_MONTEIRO_Oral_administration_of_buparvaquone_nanostructured_lipid_carrier_enables_2022.PDFpublishedVersion (English)3.7 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.